We are live on ! Find out more
GWPH

GW Pharmaceuticals Plc American Depositary Shares
GWPH

Delisted

GWPH was delisted on the 4th of May, 2021.

170 hedge funds and large institutions have $1.91B invested in GW Pharmaceuticals Plc American Depositary Shares in 2017 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 60 increasing their positions, 51 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more funds holding in top 10

Funds holding in top 10: 34 (+1)

18% more repeat investments, than reductions

Existing positions increased: 60 | Existing positions reduced: 51

5% less funds holding

Funds holding: 179170 (-9)

16% less capital invested

Capital invested by funds: $2.28B → $1.91B (-$376M)

24% less first-time investments, than exits

New positions opened: 25 | Existing positions closed: 33

33% less call options, than puts

Call options by funds: $42.3M | Put options by funds: $63.5M

Holders
170
Holders Change
-9
Holders Change %
-5.03%
% of All Funds
4.24%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.1%
New
25
Increased
60
Reduced
51
Closed
33
Calls
$42.3M
Puts
$63.5M
Net Calls
-$21.2M
Net Calls Change
-$13.6M
Name Holding Trade Value Shares
Change
Change in
Stake
AIM
151
Advantage Investment Management
Iowa
$5K
CHC
152
City Holding Co
West Virginia
$5K
MWM
153
MinichMacGregor Wealth Management
New York
$4K -$6.46K -60 -60%
SIAP
154
Sterling Investment Advisors (Pennsylvania)
Pennsylvania
$4K
Fifth Third Bancorp
155
Fifth Third Bancorp
Ohio
$3K
HDIM
156
Hanson & Doremus Investment Management
Vermont
$3K
Bessemer Group
157
Bessemer Group
New Jersey
$2K
FBT
158
First Bank & Trust
South Dakota
$2K
RFA
159
Reilly Financial Advisors
California
$2K
WAS
160
Winch Advisory Services
Wisconsin
$2K +$646 +6 +46%
TIM
161
Tortoise Investment Management
New York
$2K +$1.94K +18 New
GI
162
Gradient Investments
Minnesota
$2K +$2.26K +21 New
GT
163
Glenmede Trust
Pennsylvania
$1K
GRP
164
Global Retirement Partners
California
$1K
WA
165
WealthTrust-Arizona
Arizona
$1K
IWM
166
IHT Wealth Management
Illinois
$108 +$10.8K +100 +18%
Walleye Trading
167
Walleye Trading
New York
$80 +$85.7K +796 New
FCM
168
Farallon Capital Management
California
-$30.2M -250,000 Closed
Bank of New York Mellon
169
Bank of New York Mellon
New York
-$28.3M -233,831 Closed
Nomura Holdings
170
Nomura Holdings
Japan
-$9.39M -77,687 Closed
JP
171
Jana Partners
New York
-$7.96M -65,844 Closed
CLCM
172
Crawford Lake Capital Management
New Jersey
-$4.18M -34,536 Closed
GC
173
Guggenheim Capital
Illinois
-$1.93M -15,935 Closed
HT
174
HAP Trading
New York
-$1.68M -13,900 Closed
LMIM
175
Lockheed Martin Investment Management
Maryland
-$1.19M -9,800 Closed

GWPH Hedge Fund Activity: Q2 2017 in Review

170 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in GW Pharmaceuticals Plc American Depositary Shares (GWPH) for Q2 2017, worth a combined $1.91B — down 16% from $2.28B a quarter earlier.

Sellers outnumbered buyers: 33 funds closed out of GWPH and 25 opened new positions — a net loss of 8 holders — while 51 trimmed existing stakes and 60 added.

The largest buyer was Janus Henderson Group, opening a new position worth an estimated $75.3M. The largest seller was Fidelity Investments, cutting an estimated $37.2M.

  • 170 institutional investors held GW Pharmaceuticals Plc American Depositary Shares (GWPH) as of Q2 2017, down from 179 in Q1 2017.
  • Funds reported $1.91B of GW Pharmaceuticals Plc American Depositary Shares stock for Q2 2017, down 16% quarter-over-quarter.
  • 25 funds opened new GW Pharmaceuticals Plc American Depositary Shares positions in Q2 2017 and 33 closed out, a net change of -8 holders.
  • The largest GW Pharmaceuticals Plc American Depositary Shares buyer in Q2 2017 was Janus Henderson Group, an estimated $75.3M added.
  • The largest GW Pharmaceuticals Plc American Depositary Shares seller in Q2 2017 was Fidelity Investments, an estimated $37.2M sold.

Based on aggregated 13F filings for Q2 2017.